Skip to content

Eyhance Autorefraction Study

Repeatability of Post-operative Refraction in Patients With a Novel CE Marked Monofocal Intraocular Lens

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04572334
Enrollment
100
Registered
2020-10-01
Start date
2020-10-31
Completion date
2021-03-31
Last updated
2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract Senile

Brief summary

Since 2018, the Tecnis Eyhance ICB00 lens (Johnson&Johnson Vision, AMO Germany GmbH) was introduced, which is a monofocal IOL which has the ability of extended depth of focus improving intermediate vision without the photic phenomena specific for the multifocal IOLs. The Tecnis Eyhance ICB00 is one of our standard IOL, routinely used in our clinic. There is no single outcome measurement that can be thought of as summarizing the efficacy of an IOL, nevertheless visual acuity and refractive outcome are the most important parameters for evaluation. Aim of this study is to determine the comparability and reproducibility of different refraction methods in patients implanted with Eyhance lens and compare the outcomes with ZCB00 lens.

Detailed description

This a prospective observational study that would include pseudophakic patients that have undergone cataract surgery 2 to 12 months prior. A written informed consent will be obtained from each patient. Patients with ICB00 or ZCB00 implanted lenses will be included. Autorefraction measurements will be performed consecutively, each patient will be measured three times with each device. Two independent observers will perform subjective refraction and will be masked to the autorefraction outcome. We would like to include 50 eyes with ICB00 and 50 eyes with ZCB00 lens implanted. For the estimation of sample size, we used data from Wang et al. (Wang L, Misra M, Palikaris IG, Koch DD. J Cataract Refract Surg 2002; 28: 276-282) that compared the refractive outcome of pseudophakic eyes and determined a mean spherical equivalent of -0.76 + 0.96 D for group I and -0.44 + 1.13 for group II, thus leading to an effect size of 0.2. The effect size was used for ANOVA test for repeated measurements within factor, with alpha \< 0.05, power of 80% and a correlation of 0.5 between the two groups gave us an estimated of sample size of 42 patient. To allow patient drop out a number of 50 eyes will be included per lens group (in total 100 eyes). When different lenses are implanted (one eye received ZCB00 and the other Eyhance), than both eyes of the patient will be included.

Interventions

OTHERAuto and Subjective Refraction

All patients will be measured with three autorefractometers and two independent observes will perform subjective refraction

Sponsors

Vienna Institute for Research in Ocular Surgery
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* 21 years old or above * Operated age-related cataract (pseudophakic patient) * Tecnis Eyhance ICB00 or Tecnis ZCB00 IOL implanted within 2 to 12 months prior to study related examination

Exclusion criteria

* Intra- or Postoperative complication * patients with severe corneal pathology, severe macular degeneration, severe diabetic retinopathy, etc. that would significantly influence visual outcome * nystagmus or pathologies that would affect patient fixation * pregnancy- for women in reproductive age a pregnancy test will be performed.

Design outcomes

Primary

MeasureTime frame
Reproducibility of different refraction methods2-12 months

Secondary

MeasureTime frame
Comparability between the devices (autorefractometers)2-12 months

Countries

Austria

Contacts

Primary ContactOliver Findl, Prof., MD
office@viros.at+43 1 91021 57564
Backup ContactNino Hirnschall, MD, PhD
nino.hirnschall@googlemail.com+43 1 91021 57564

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026